Gut check: could your microbiome boost lymphoma therapy?
NCT ID NCT07498920
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether the bacteria living in your gut can influence how well a drug called glofitamab works against diffuse large B-cell lymphoma (DLBCL). Researchers will collect stool samples from 30 patients before and after treatment to track changes in gut microbiome and see if they relate to treatment response or side effects. The goal is to understand if the gut microbiome can be used to improve outcomes for lymphoma patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal how gut bacteria influence the effectiveness of glofitamab in lymphoma patients, potentially guiding future personalized treatments.
- What could go wrong
- This is a small, early observational study (30 people) that does not test a new treatment. It may not find a clear link between gut microbiome and therapy outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma
- Off-the-Shelf immune cells take on tough lymphoma
- New cocktail aims to tame aggressive lymphoma in the very elderly
- New hope for aggressive lymphoma: triple-drug combo enters human trials
- New drug cocktail aims to tackle tough lymphoma